Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6127197,time to peak,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,2.99,10627,DB01595,Nitrazepam
,6127197,elimination half-life,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,14.7,10628,DB01595,Nitrazepam
,456400,beta-phase half-life,"After a single oral dose of nitrazepam 5 mg the most prominent differences between the experimental groups were in the beta-phase half-life mean 29 h in the young volunteers and 40 h in geriatric patients , and in the apparent volume of distribution during the beta-phase of 2.4 vs 4.8 1/kg.",Human pharmacokinetics of nitrazepam: effect of age and diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/456400/),h,29,11614,DB01595,Nitrazepam
,456400,beta-phase half-life,"After a single oral dose of nitrazepam 5 mg the most prominent differences between the experimental groups were in the beta-phase half-life mean 29 h in the young volunteers and 40 h in geriatric patients , and in the apparent volume of distribution during the beta-phase of 2.4 vs 4.8 1/kg.",Human pharmacokinetics of nitrazepam: effect of age and diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/456400/),h,40,11615,DB01595,Nitrazepam
,456400,apparent volume of distribution during the beta-phase,"After a single oral dose of nitrazepam 5 mg the most prominent differences between the experimental groups were in the beta-phase half-life mean 29 h in the young volunteers and 40 h in geriatric patients , and in the apparent volume of distribution during the beta-phase of 2.4 vs 4.8 1/kg.",Human pharmacokinetics of nitrazepam: effect of age and diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/456400/),[1] / [kg],2.4,11616,DB01595,Nitrazepam
,456400,apparent volume of distribution during the beta-phase,"After a single oral dose of nitrazepam 5 mg the most prominent differences between the experimental groups were in the beta-phase half-life mean 29 h in the young volunteers and 40 h in geriatric patients , and in the apparent volume of distribution during the beta-phase of 2.4 vs 4.8 1/kg.",Human pharmacokinetics of nitrazepam: effect of age and diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/456400/),[1] / [kg],4.8,11617,DB01595,Nitrazepam
,1629384,elimination half-life,Patients and control subjects did not differ significantly in nitrazepam elimination half-life (32 vs. 24 hour) or volume of distribution (4.2 vs. 3.6 liters/kg).,Nitrazepam clearance unimpaired in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),h,32,14769,DB01595,Nitrazepam
,1629384,elimination half-life,Patients and control subjects did not differ significantly in nitrazepam elimination half-life (32 vs. 24 hour) or volume of distribution (4.2 vs. 3.6 liters/kg).,Nitrazepam clearance unimpaired in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),h,24,14770,DB01595,Nitrazepam
,1629384,volume of distribution,Patients and control subjects did not differ significantly in nitrazepam elimination half-life (32 vs. 24 hour) or volume of distribution (4.2 vs. 3.6 liters/kg).,Nitrazepam clearance unimpaired in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),[l] / [kg],4.2,14771,DB01595,Nitrazepam
,1629384,volume of distribution,Patients and control subjects did not differ significantly in nitrazepam elimination half-life (32 vs. 24 hour) or volume of distribution (4.2 vs. 3.6 liters/kg).,Nitrazepam clearance unimpaired in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),[l] / [kg],3.6,14772,DB01595,Nitrazepam
,1629384,Clearance,"Clearance was higher in patients than in controls (4.2 vs. 1.7 ml/min/kg), but the difference was not significant.",Nitrazepam clearance unimpaired in patients with renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),[ml] / [kg·min],4.2,14773,DB01595,Nitrazepam
,1629384,Clearance,"Clearance was higher in patients than in controls (4.2 vs. 1.7 ml/min/kg), but the difference was not significant.",Nitrazepam clearance unimpaired in patients with renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),[ml] / [kg·min],1.7,14774,DB01595,Nitrazepam
,1629384,free fraction,"Nitrazepam free fraction in serum was increased in renal patients (16.8 vs. 15.0% unbound, p = 0.08).",Nitrazepam clearance unimpaired in patients with renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),%·unbound,16.8,14775,DB01595,Nitrazepam
,1629384,free fraction,"Nitrazepam free fraction in serum was increased in renal patients (16.8 vs. 15.0% unbound, p = 0.08).",Nitrazepam clearance unimpaired in patients with renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629384/),%·unbound,15.0,14776,DB01595,Nitrazepam
,17286787,time to peak,"For nitrazepam and diazepam, the time to peak was delayed about 1 h in fed condition (P > 0.05).","Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,1,19560,DB01595,Nitrazepam
,17286787,Reaction time,Reaction time of quazepam with light food was prolonged at 4 and 6 h after dosing and its area under the effect-time curve from 0 to 10 h was increased (P < 0.05).,"Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,4,19561,DB01595,Nitrazepam
,17286787,Reaction time,Reaction time of quazepam with light food was prolonged at 4 and 6 h after dosing and its area under the effect-time curve from 0 to 10 h was increased (P < 0.05).,"Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,6,19562,DB01595,Nitrazepam
,832658,half life,"The half life of the drug, however, may vary appreciably from subject to subject, ranging from 54 to 198 h.",Pharmacokinetic aspects of protriptyline plasma levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832658/),h,54 to 198,24268,DB01595,Nitrazepam
,1783647,limit of detection,The limit of detection is 15.5 ng/ml and the limit of quantitation is 46.5 ng/ml.,Determination of temazepam and temazepam glucuronide by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783647/),[ng] / [ml],15.5,72358,DB01595,Nitrazepam
,1783647,limit of quantitation,The limit of detection is 15.5 ng/ml and the limit of quantitation is 46.5 ng/ml.,Determination of temazepam and temazepam glucuronide by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783647/),ng,46,72359,DB01595,Nitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],4.8,77646,DB01595,Nitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],7.2,77647,DB01595,Nitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],17.9,77648,DB01595,Nitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,9.3,77649,DB01595,Nitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,23,77650,DB01595,Nitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,63,77651,DB01595,Nitrazepam
,7130314,minimum detection range,The minimum detection range of each compound was approximately 2.5 ng per 100-microliter sample.,Determination of diazepam and its pharmacologically active metabolites in blood by bond Elut column extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7130314/),-1·ng,2.5,82713,DB01595,Nitrazepam
,2874007,half-life,"As loprazolam has a half-life of 7 to 8 hours in healthy adults it may have advantages over longer-acting hypnotics, particularly when residual sedative effects on the day after ingestion are undesirable, although at doses greater than 1 mg residual sedation may occur.",Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874007/),h,7 to 8,84334,DB01595,Nitrazepam
,3790401,peak nitrazepam plasma concentration,Comparison of peak nitrazepam plasma concentration (94.2 +/- 10.3-obese vs 119 +/- 14.6 ng ml-1; NS) and time required after drug administration to reach peak concentration (1.52 +/- 0.24-obese vs 1.59 +/- 0.36 h; NS) indicated no differences between obese and control subjects.,Obesity effects on nitrazepam disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[ng] / [ml],94.2,88480,DB01595,Nitrazepam
,3790401,peak nitrazepam plasma concentration,Comparison of peak nitrazepam plasma concentration (94.2 +/- 10.3-obese vs 119 +/- 14.6 ng ml-1; NS) and time required after drug administration to reach peak concentration (1.52 +/- 0.24-obese vs 1.59 +/- 0.36 h; NS) indicated no differences between obese and control subjects.,Obesity effects on nitrazepam disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[ng] / [ml],119,88481,DB01595,Nitrazepam
,3790401,time required after drug administration to reach peak concentration,Comparison of peak nitrazepam plasma concentration (94.2 +/- 10.3-obese vs 119 +/- 14.6 ng ml-1; NS) and time required after drug administration to reach peak concentration (1.52 +/- 0.24-obese vs 1.59 +/- 0.36 h; NS) indicated no differences between obese and control subjects.,Obesity effects on nitrazepam disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),h,1.52,88482,DB01595,Nitrazepam
,3790401,time required after drug administration to reach peak concentration,Comparison of peak nitrazepam plasma concentration (94.2 +/- 10.3-obese vs 119 +/- 14.6 ng ml-1; NS) and time required after drug administration to reach peak concentration (1.52 +/- 0.24-obese vs 1.59 +/- 0.36 h; NS) indicated no differences between obese and control subjects.,Obesity effects on nitrazepam disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),h,1.59,88483,DB01595,Nitrazepam
,3790401,Elimination half-life,Elimination half-life was markedly increased in obese subjects (33.5 +/- 2.2 vs 23.9 +/- 1.2 h; P less than 0.001) due to increased apparent volume of distribution (Vd) (290 +/- 45 vs 137 +/- 12 l; P less than 0.005).,Obesity effects on nitrazepam disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),h,33.5,88484,DB01595,Nitrazepam
,3790401,Elimination half-life,Elimination half-life was markedly increased in obese subjects (33.5 +/- 2.2 vs 23.9 +/- 1.2 h; P less than 0.001) due to increased apparent volume of distribution (Vd) (290 +/- 45 vs 137 +/- 12 l; P less than 0.005).,Obesity effects on nitrazepam disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),h,23.9,88485,DB01595,Nitrazepam
,3790401,apparent volume of distribution (Vd),Elimination half-life was markedly increased in obese subjects (33.5 +/- 2.2 vs 23.9 +/- 1.2 h; P less than 0.001) due to increased apparent volume of distribution (Vd) (290 +/- 45 vs 137 +/- 12 l; P less than 0.005).,Obesity effects on nitrazepam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),l,290,88486,DB01595,Nitrazepam
,3790401,apparent volume of distribution (Vd),Elimination half-life was markedly increased in obese subjects (33.5 +/- 2.2 vs 23.9 +/- 1.2 h; P less than 0.001) due to increased apparent volume of distribution (Vd) (290 +/- 45 vs 137 +/- 12 l; P less than 0.005).,Obesity effects on nitrazepam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),l,137,88487,DB01595,Nitrazepam
,3790401,Oral clearance,Oral clearance was also increased in the obese subjects (101 +/- 12.4 vs 66.8 +/- 12.4 ml min-1; P less than 0.02).,Obesity effects on nitrazepam disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[ml] / [min],101,88488,DB01595,Nitrazepam
,3790401,Oral clearance,Oral clearance was also increased in the obese subjects (101 +/- 12.4 vs 66.8 +/- 12.4 ml min-1; P less than 0.02).,Obesity effects on nitrazepam disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[ml] / [min],66.8,88489,DB01595,Nitrazepam
,3790401,% unbound,Extent of nitrazepam binding to plasma proteins was slightly decreased in obese subjects (% unbound--19.7 +/- 0.4-obese vs 17.9 +/- 0.3%; P less than 0.005).,Obesity effects on nitrazepam disposition. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),%,19.7,88490,DB01595,Nitrazepam
,3790401,% unbound,Extent of nitrazepam binding to plasma proteins was slightly decreased in obese subjects (% unbound--19.7 +/- 0.4-obese vs 17.9 +/- 0.3%; P less than 0.005).,Obesity effects on nitrazepam disposition. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),%,17.9,88491,DB01595,Nitrazepam
,3790401,Vd,Correction of both Vd (2.62 +/- 0.17-obese vs 2.22 +/- 0.19 l kg-1; NS) and clearance (0.93 +/- 0.06-obese +/- 1.07 +/- 0.07 ml min-1 kg-1; NS) for total body weight (TBW) suggested that increases in obese subjects of both of these parameters were a function of body weight.,Obesity effects on nitrazepam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[l] / [kg],2.62,88492,DB01595,Nitrazepam
,3790401,Vd,Correction of both Vd (2.62 +/- 0.17-obese vs 2.22 +/- 0.19 l kg-1; NS) and clearance (0.93 +/- 0.06-obese +/- 1.07 +/- 0.07 ml min-1 kg-1; NS) for total body weight (TBW) suggested that increases in obese subjects of both of these parameters were a function of body weight.,Obesity effects on nitrazepam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[l] / [kg],2.22,88493,DB01595,Nitrazepam
,3790401,clearance,Correction of both Vd (2.62 +/- 0.17-obese vs 2.22 +/- 0.19 l kg-1; NS) and clearance (0.93 +/- 0.06-obese +/- 1.07 +/- 0.07 ml min-1 kg-1; NS) for total body weight (TBW) suggested that increases in obese subjects of both of these parameters were a function of body weight.,Obesity effects on nitrazepam disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790401/),[ml] / [kg·min],0.93,88494,DB01595,Nitrazepam
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.3,94875,DB01595,Nitrazepam
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.7,94876,DB01595,Nitrazepam
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,29.6,94877,DB01595,Nitrazepam
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],59.3,94878,DB01595,Nitrazepam
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],58.2,94879,DB01595,Nitrazepam
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],55.8,94880,DB01595,Nitrazepam
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,30.6,94881,DB01595,Nitrazepam
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,31.2,94882,DB01595,Nitrazepam
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],46.6,94883,DB01595,Nitrazepam
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],45.6,94884,DB01595,Nitrazepam
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,11.4,94885,DB01595,Nitrazepam
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,12.4,94886,DB01595,Nitrazepam
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,13.5,94887,DB01595,Nitrazepam
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],323,94888,DB01595,Nitrazepam
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],530,94889,DB01595,Nitrazepam
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],459,94890,DB01595,Nitrazepam
,6138889,percentage recoveries,"The percentage recoveries of nitrazepam and temazepam were 79% and 85%, respectively.",Determination of nitrazepam and temazepam in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138889/),%,79,109497,DB01595,Nitrazepam
,6138889,percentage recoveries,"The percentage recoveries of nitrazepam and temazepam were 79% and 85%, respectively.",Determination of nitrazepam and temazepam in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138889/),%,85,109498,DB01595,Nitrazepam
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB01595,Nitrazepam
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB01595,Nitrazepam
,11301565,Clearance,"Clearance of nitrazepam was 0.91 +/- 0.165 mL/min/kg and 1.17 +/- 0.492 mL/min/kg, and half-life (t1/2) was 22.1 +/- 4.96 hours and 21.5 +/- 7.51 hours for the Japanese and European groups, respectively.",Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301565/),[ml] / [kg·min],0.91,126975,DB01595,Nitrazepam
,11301565,Clearance,"Clearance of nitrazepam was 0.91 +/- 0.165 mL/min/kg and 1.17 +/- 0.492 mL/min/kg, and half-life (t1/2) was 22.1 +/- 4.96 hours and 21.5 +/- 7.51 hours for the Japanese and European groups, respectively.",Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301565/),[ml] / [kg·min],1.17,126976,DB01595,Nitrazepam
,11301565,half-life (t1/2),"Clearance of nitrazepam was 0.91 +/- 0.165 mL/min/kg and 1.17 +/- 0.492 mL/min/kg, and half-life (t1/2) was 22.1 +/- 4.96 hours and 21.5 +/- 7.51 hours for the Japanese and European groups, respectively.",Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301565/),h,22.1,126977,DB01595,Nitrazepam
,11301565,half-life (t1/2),"Clearance of nitrazepam was 0.91 +/- 0.165 mL/min/kg and 1.17 +/- 0.492 mL/min/kg, and half-life (t1/2) was 22.1 +/- 4.96 hours and 21.5 +/- 7.51 hours for the Japanese and European groups, respectively.",Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301565/),h,21.5,126978,DB01595,Nitrazepam
,474154,peak concentrations,"The peak concentrations in serum and saliva were 40.7 and 1.9 ng/ml (P less than 0.001) and the times to reach the peak maximum 2.4 and 2.5 hours, respectively (difference not significant).",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),[ng] / [ml],40.7,159575,DB01595,Nitrazepam
,474154,peak concentrations,"The peak concentrations in serum and saliva were 40.7 and 1.9 ng/ml (P less than 0.001) and the times to reach the peak maximum 2.4 and 2.5 hours, respectively (difference not significant).",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),[ng] / [ml],1.9,159576,DB01595,Nitrazepam
,474154,times to reach the peak maximum,"The peak concentrations in serum and saliva were 40.7 and 1.9 ng/ml (P less than 0.001) and the times to reach the peak maximum 2.4 and 2.5 hours, respectively (difference not significant).",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),h,2.4,159577,DB01595,Nitrazepam
,474154,times to reach the peak maximum,"The peak concentrations in serum and saliva were 40.7 and 1.9 ng/ml (P less than 0.001) and the times to reach the peak maximum 2.4 and 2.5 hours, respectively (difference not significant).",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),h,2.5,159578,DB01595,Nitrazepam
,474154,half-life,"The mean half-life of nitrazepam in serum was 30.5 hrs and in saliva 39.9 hrs, the difference being significant at P less than 0.05.",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),h,30.5,159579,DB01595,Nitrazepam
,474154,half-life,"The mean half-life of nitrazepam in serum was 30.5 hrs and in saliva 39.9 hrs, the difference being significant at P less than 0.05.",Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474154/),h,39.9,159580,DB01595,Nitrazepam
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB01595,Nitrazepam
,3281819,elimination half-life,"Brotizolam has an elimination half-life of about 5 hours, which is 'intermediate' compared with the shorter-acting hypnotic, triazolam, and longer-acting benzodiazepines.","Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3281819/),h,5,208420,DB01595,Nitrazepam
,621234,sensitivity limit,The sensitivity limit of the method is about 1 ng/ml plasma for both drugs.,Assay of underivatized intrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/621234/),[ng] / [ml],1,210779,DB01595,Nitrazepam
,621234,elimination half-life,The mean elimination half-life of nitrazepam was 27 h (range 13-34 h).,Assay of underivatized intrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/621234/),h,27,210780,DB01595,Nitrazepam
,1943053,detection limit,The detection limit was 0.5 ng/mL and linearity was obtained in the range of 1-200 ng/mL.,A rapid and sensitive quantitation of Amitraz in plasma by gas chromatography with nitrogen-phosphorus detection and its application for pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1943053/),[ng] / [ml],0.5,213774,DB01595,Nitrazepam
,474153,total excreted urinary metabolites,The interindividual variation of total excreted urinary metabolites was large ranging between 848-4933 microgram (17-99% of the dose during 7 days).,Urinary elimination of nitrazepam and its main metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474153/),μg,848-4933,267908,DB01595,Nitrazepam
,474153,urinary half-lives,"The urinary half-lives of free and conjugated-7-aminonitrazepam were (mean and ranges) 44 (23-65) and 46 (25-69) hrs, and of 7-acetamidonitrazepam 12 (5-31) and 18 (5-46) hrs, respectively.",Urinary elimination of nitrazepam and its main metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474153/),h,44,267909,DB01595,Nitrazepam
,474153,urinary half-lives,"The urinary half-lives of free and conjugated-7-aminonitrazepam were (mean and ranges) 44 (23-65) and 46 (25-69) hrs, and of 7-acetamidonitrazepam 12 (5-31) and 18 (5-46) hrs, respectively.",Urinary elimination of nitrazepam and its main metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474153/),h,46,267910,DB01595,Nitrazepam
,474153,urinary half-lives,"The urinary half-lives of free and conjugated-7-aminonitrazepam were (mean and ranges) 44 (23-65) and 46 (25-69) hrs, and of 7-acetamidonitrazepam 12 (5-31) and 18 (5-46) hrs, respectively.",Urinary elimination of nitrazepam and its main metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474153/),h,12,267911,DB01595,Nitrazepam
,474153,urinary half-lives,"The urinary half-lives of free and conjugated-7-aminonitrazepam were (mean and ranges) 44 (23-65) and 46 (25-69) hrs, and of 7-acetamidonitrazepam 12 (5-31) and 18 (5-46) hrs, respectively.",Urinary elimination of nitrazepam and its main metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474153/),h,18,267912,DB01595,Nitrazepam
